Tirzepatide showed no significant differences in surgery rates when compared with other agents: Naltrexone/Bupropion (HR 0.81, 95% CI 0.631.05, p = 0.11), Phentermine/Topiramate (HR 0.43, 95% CI 0.082.23, p = 0.30), or Phentermine (HR 3.21, 95% CI 0.6116.91, p = 0.15)
Your healthcare provider should review your family history and metabolic markers before starting and annually during long-term therapy
The active ingredient tirzepatides mechanism supports glycemic control, reduced appetite, and weight loss by activating two key incretin pathways offering greater clinical benefits than traditional GLP-1 therapies
The pharmaceutical giant said in its fourth-quarter earnings release that tirzepatide showed positive results in a phase two trial as a treatment for a serious form of liver disease called metabolic dysfunction-associated steatohepatitis, or MASH